Z 335

Drug Profile

Z 335

Latest Information Update: 31 Oct 2005

Price : $50

At a glance

  • Originator Zeria
  • Class Antiplatelets; Vascular disorder therapies
  • Mechanism of Action Thromboxane A2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Arterial occlusive disorders

Most Recent Events

  • 24 Oct 2005 Discontinued - Phase-II for Arterial occlusive disorders in Japan (PO)
  • 30 Jul 2002 A preclinical study has been added to the pharmacokinetics and Ischaemic Heart Disease and Thromboses pharmacodynamics sections
  • 26 Aug 1999 Phase-II clinical trials for Arterial occlusive disorders in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top